Stage 1 bladder cancer typically appears as a small, cauliflower-like growth attached to the inner lining of the bladder. These tumors are usually visible during cystoscopy, a procedure where a tiny camera is inserted into the bladder through the urethra. What defines stage 1 specifically is that the tumor has grown past the bladder’s inner lining into the connective tissue beneath it, called the lamina propria, but has not reached the muscle layer of the bladder wall.
How It Looks During Cystoscopy
Most stage 1 bladder tumors have a papillary shape, meaning they grow outward from the bladder wall on thin, finger-like stalks. They often resemble a small cauliflower or sea anemone. The surface is typically irregular, and the color ranges from pinkish-red to darker red depending on blood supply. Some tumors appear as a single growth, while others show up as clusters.
Not all stage 1 tumors look the same. A related form called carcinoma in situ (CIS), which can coexist with a stage 1 tumor, appears as a flat, red, velvety patch on the bladder lining rather than a raised growth. CIS doesn’t form a visible mass, which makes it harder to spot. When a doctor sees both a papillary tumor and flat red patches during cystoscopy, that combination usually signals a more aggressive situation.
Stage 1 tumors can be difficult to distinguish visually from stage 0a tumors, which also look like thin growths extending into the bladder’s open space. The critical difference isn’t visible to the naked eye. It only becomes clear when a pathologist examines tissue samples under a microscope and determines whether cancer cells have pushed into the connective tissue layer below the surface.
What It Looks Like on Imaging
On a CT scan, stage 1 bladder cancer may show up as a nodule or area of irregular wall thickening inside the bladder. These tumors tend to absorb contrast dye more readily than normal tissue, so they often appear as a bright spot on early-phase images when the surrounding urine is still dark. A discrete mass or area of focal wall thickening that looks nodular or uneven is considered suspicious. Diffuse, smooth thickening of the entire bladder wall, on the other hand, is rarely cancer.
In some cases, calcification along the bladder wall or a filling defect (a spot where dye doesn’t flow smoothly) can also raise concern. However, CT scans alone cannot reliably distinguish between stage 0 and stage 1 disease. Cystoscopy with tissue sampling remains the definitive way to diagnose and stage the tumor.
What You Notice as Symptoms
The most common sign of stage 1 bladder cancer is blood in the urine. This can make urine appear bright red or cola-colored, but in many cases the blood is microscopic and only detected through a lab test. The bleeding is often painless and intermittent, which leads some people to dismiss it or assume it’s a urinary tract infection.
Other symptoms can include needing to urinate more frequently than usual, a burning sensation during urination, or feeling like you need to go urgently even when your bladder isn’t full. These overlap heavily with common, benign conditions, which is part of why bladder cancer sometimes goes undetected in its early stages.
What Defines Stage 1 Under a Microscope
The bladder wall has several layers. From the inside out: a thin lining of cells (the urothelium), a layer of connective tissue (the lamina propria), and then thick muscle. In stage 0, cancer cells sit only within the lining. In stage 1, they’ve broken through the lining and invaded the connective tissue, but they haven’t reached the muscle. Once cancer penetrates the muscle, it becomes stage 2, which is a significantly different situation requiring more aggressive treatment.
Stage 1 tumors account for roughly 5% to 20% of non-muscle-invasive bladder cancers. Most are classified as high-grade, meaning the cells look very abnormal under a microscope and are more likely to grow and spread. Some aggressive subtypes exist within stage 1, including small-cell variants and tumors that have invaded the tiny blood or lymph vessels in the connective tissue layer.
How Stage 1 Is Diagnosed and Treated
The primary procedure for both diagnosing and initially treating stage 1 bladder cancer is called a TURBT (transurethral resection of bladder tumor). Under anesthesia, a surgeon inserts a specialized scope through the urethra and removes the visible tumor in layers. The tissue is sent to a pathologist who determines how deep the cancer has grown and how abnormal the cells appear. If the tissue sample doesn’t clearly include muscle from the bladder wall, a repeat procedure is often needed to confirm the cancer hasn’t gone deeper than it initially appeared.
For most stage 1 tumors, particularly high-grade ones, doctors follow the initial removal with a course of immunotherapy delivered directly into the bladder. This treatment uses a weakened form of a tuberculosis bacterium (BCG) to stimulate the immune system to attack any remaining cancer cells. The standard schedule involves weekly treatments for six weeks, followed by shorter maintenance courses that can continue for up to three years. This maintenance approach has been shown to roughly double the time patients remain cancer-free compared to the initial six-week course alone.
Recurrence and Outlook
Stage 1 bladder cancer has a meaningful tendency to come back. The five-year recurrence rate is approximately 42%, and between 20% and 40% of stage 1 tumors progress to a more advanced stage over that same period. This is why regular follow-up cystoscopies, typically every three to six months in the first few years, are a central part of managing the disease.
The five-year relative survival rate for localized bladder cancer (cancer that hasn’t spread beyond the bladder) is 71%, according to the National Cancer Institute. Because stage 1 falls within this localized category and hasn’t reached the muscle wall, many patients do well with the combination of tumor removal and ongoing immunotherapy. The key factor influencing outcomes is tumor grade: high-grade stage 1 tumors carry a higher risk of recurrence and progression than low-grade ones, and they require more intensive surveillance and treatment.